• TBD Pharmatech at DCAT Week 2023

    TBD Pharmatech at DCAT Week 2023

    March 20-23 2023 TBD Pharmatech will be present at DCAT Week 2023! This is the first time TBD Pharmatech is attending DCAT Week. We are already looking forward to discuss CDMO collaboration! Book a meeting with TBD Pharmatech’s CBO Olga Tšubrik via LinkedIn, contact us via webpage or write directly to sales@tbdpharmatech.com. DCAT Week 2023 is the premier global event held annually in New York City for companies engaged in the Bio and Pharmaceutical Manufacturing Value Chain. It is hosted by the Drug, Chemical & Associated Technologies Association (DCAT), a not-for-profit, member-supported, global business development association whose unique membership model

    Read more
  • What are inactive pharmaceutical ingredients?

    What are inactive pharmaceutical ingredients?

    Inactive pharmaceutical ingredients (IPIs) are ingredients found in medication that do not directly affect the treatment of a disease or condition. While they may not be active, these components can still have an impact on the overall effectiveness of a drug. Understanding IPIs is important to ensure that your medications are working as intended. What do IPIs do? Inactive pharmaceutical ingredients come in many forms and serve a variety of purposes. For example, some are used as fillers and binding agents to help make tablets more consistent in size and shape. Others, such as colorings, flavorings, and preservatives, may be

    Read more
  • Project: PET-Diagnostics in collaboration with PharmIdea

    Project: PET-Diagnostics in collaboration with PharmIdea

    TBD Pharmatech worked on a PET-diagnostics project together with Latvian partner SIA PharmIdea from 2017 until 2019. The main objective of the Project was to develop a PET-product used in Positron emission tomography-computer tomography (PET-CT) for cancer, Alzheimer or Parkinson diagnostics. The outcome of the Project was final dosage form of the PET-product with all the documentation package, necessary for its implementation in nuclear medicine centers and hospitals. After the first Product has been developed and marketed, TBD and PharmIdea plan to continue the cooperation and develop the next PET-diagnostics and other products for oncology studies, studies of Alzheimer and

    Read more
  • LIOS and TBD Pharmatech join forces

    LIOS and TBD Pharmatech join forces

    On 21st February 2023, the Latvian Institute of Organic Synthesis (LIOS) and TBD Pharmatech signed the Memorandum of Understanding to strengthen the drug manufacturing performance of the Baltic region. The alliance will perform joint projects for manufacturing technology development and the production of active pharmaceutical ingredients (APIs). It will also support and promote new trends in API manufacturing such as the introduction of green technologies and advanced safety aspects. “Memorandum of understanding with TBD Pharmatech is a very important step forward for LIOS to become an integral part of the API technologies development ecosystem by linking our research capacities to

    Read more